Pluvicto for African American men with advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether the drug Pluvicto (also known as lutetium Lu 177 vipivotide tetraxetan) can help African American men with a type of prostate cancer that has spread and no longer responds to hormone therapy. The treatment targets a protein called PSMA found on cancer cells, which may slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and identify as African American.
- Your cancer must have spread and continued to grow despite previous hormone therapy.
- You must have tried only one second-generation hormone therapy (like abiraterone or enzalutamide) and it must be the most recent treatment.
- A PSMA scan must show your cancer has PSMA, and you must have at least one tumor visible on a CT, MRI, or bone scan.
- You must be in good physical condition (able to care for yourself and be up and about) and have adequate blood counts, liver, and kidney function.
- You cannot have had certain prior treatments (like chemotherapy or other radioligand therapies) within a specific timeframe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial tests whether giving a higher first dose of a radioactive drug (Lu-177-PSMA-617) can better treat prostate cancer that has spread and no longer responds to hormone therapy. The drug targets cancer cells and delivers radiation directly to them.
Hear when a new Stage IVB Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.